Pfizer Inc Says FY23 Revenues For Paxlovid And Comirnaty Are Expected To Be ~$12.5B
Portfolio Pulse from Benzinga Newsdesk
Pfizer Inc has projected its FY23 revenues for Paxlovid and Comirnaty to be approximately $12.5 billion.
October 13, 2023 | 8:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's FY23 revenue forecast for Paxlovid and Comirnaty is approximately $12.5 billion.
The news directly pertains to Pfizer's revenue forecast for FY23. This projection is significant as it provides investors with an insight into the company's expected financial performance. Given the importance of Paxlovid and Comirnaty to Pfizer's portfolio, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100